![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
chevron_left Bispecific Antibodies to Treat Multiple Myeloma: An Educational Guide
Introduction
Understanding Bispecific Antibodies
Eligibility and Administration
Treatment Course
Side Effects of Bispecific Antibodies
Side Effect Management and Support
FDA Approved Bispecific Antibodies
Bispecific Antibodies in Clinical Trials
Treatment Strategies with Bispecific Antibodies
Caregiver Role in Bispecific Antibody Therapy
Financial Resources for Bispecific Antibody Therapy
Future Considerations of Bispecific Antibody Therapy
Share Your Experience
Questions to Ask Your Doctor about Bispecific Antibody Therapy
Additional Resources
chevron_left Bispecific Antibodies to Treat Multiple Myeloma: An Educational Guide
Introduction
Understanding Bispecific Antibodies
Eligibility and Administration
Treatment Course
Side Effects of Bispecific Antibodies
Side Effect Management and Support
FDA Approved Bispecific Antibodies
Bispecific Antibodies in Clinical Trials
Treatment Strategies with Bispecific Antibodies
Caregiver Role in Bispecific Antibody Therapy
Financial Resources for Bispecific Antibody Therapy
Future Considerations of Bispecific Antibody Therapy
Share Your Experience
Questions to Ask Your Doctor about Bispecific Antibody Therapy
Additional Resources
Bispecific Antibody Targets
Last updated on: 8/1/2024
What bispecific antibody therapies are being tested in multiple myeloma clinical trials?
Current research is exploring bispecific antibodies that target various molecules on myeloma cells, including:
- B-cell maturation antigen (BCMA): This is a protein highly expressed on the surface of myeloma cells, making it an attractive target for bispecific antibodies.
- G protein-coupled receptor class C group 5 member D (GPRC5D): This is another protein found on myeloma cells being investigated as a target for bispecific antibodies.
- Fc receptor-like 5 (FcRL5): This molecule helps protect myeloma cells from being attacked by the immune system. Bispecific antibodies targeting FcRL5 aim to block this protective mechanism, allowing the immune system to eliminate myeloma cells.
